Bluejay Diagnostics Faces Delisting Concerns

TL;DR

Bluejay Diagnostics might get delisted - stock exchange rules are a problem.

AI Summary

Bluejay Diagnostics, Inc. filed an 8-K on March 4, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the earliest event reported on February 28, 2024. The company is incorporated in Delaware and its principal executive offices are located in Acton, MA.

Why It Matters

This filing indicates potential issues with Bluejay Diagnostics' compliance with stock exchange listing requirements, which could lead to the stock being delisted.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and investor confidence.

Key Players & Entities

• Bluejay Diagnostics, Inc. (company) — Registrant
• February 28, 2024 (date) — Earliest event reported
• March 4, 2024 (date) — Filing date
• 360 Massachusetts Avenue, Suite 203, Acton, MA 01720 (location) — Principal executive offices

FAQ

Key Financial Figures

• $1.00 — ice for its common stock had been below $1.00 for the previous 30 consecutive busines

Filing Documents

• ea0201073-8k_bluejay.htm (8-K) — 27KB
• image_001.jpg (GRAPHIC) — 5KB
• 0001213900-24-019210.txt ( ) — 206KB
• bjdx-20240228.xsd (EX-101.SCH) — 3KB
• bjdx-20240228_lab.xml (EX-101.LAB) — 33KB
• bjdx-20240228_pre.xml (EX-101.PRE) — 22KB
• ea0201073-8k_bluejay_htm.xml (XML) — 3KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . On February 28, 2024, Bluejay Diagnostics, Inc. (the "Company") received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") notifying the Company that the closing bid price for its common stock had been below $1.00 for the previous 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification has no immediate effect on the listing of the Company's common stock on The Nasdaq Capital Market. Under the Nasdaq Listing Rules, the Company has a period of 180 calendar days to regain compliance. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 or higher for a minimum of ten consecutive business days, and in such case, Nasdaq will provide the Company with written confirmation of compliance. If the Company does not regain compliance by August 26, 2024, the Company may be eligible for an additional 180 calendar days, provided the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except the bid price requirement, and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period. If the Company is not eligible or it appears to Nasdaq that the Company will not be able to cure the deficiency during the second compliance period, Nasdaq will provide written notice to the Company that the Company's common stock will be subject to delisting. In the event of such notification, the Company may appeal Nasdaq's determination to delist its securities, but there can be no assurance that Nasdaq would grant the Company's request for continued listing. The Company

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Bluejay Diagnostics, Inc. By: /s/ Neil Dey Neil Dey Chief Executive Officer Date: March 1, 2024 2